History

Steripak was started in 1980 by John & Ernest Prebble, with a 49% share, and Schering AG, with a 51% share. 

There were ten employees and one production machine in Runcorn, and the objective was to become the major European Pharmaceutical contract manufacturer for sterile liquids using the process of Blow Fill Seal (BFS).

In 1985 Schering AG acquired the whole company and used the platform to launch its UK business.

In 1987 Waverley Pharmaceuticals acquired the whole share capital of Steripak from Schering AG, a company with staff experienced in the manufacturing of BFS products. The first batch of products was produced in October 1987. At that point, there were 34 people employed. Within two years, this increased to over 200 members of staff.

In 1992, Steripak was bought by the IVAX Corporation of Miami and became part of the Norton Healthcare Group of Companies. Norton Healthcare specialises in the manufacture of generic pharmaceutical products. In October 2001 the Norton Healthcare Group changed its name and became IVAX Pharmaceuticals UK Ltd. In January 2006, the IVAX corporation was acquired by Teva Pharmaceutical industries (headquartered in Israel). Teva was founded in 1901 and by the 1990s its worldwide presence was established. In the 2000s Teva became one of the top 20 global pharmaceutical companies and by 2006 became the world's largest generic pharmaceutical company. Currently, there are c46,000 employees of Teva across the globe.

History Of Teva Pharmaceuticals

Founded in Jerusalem in 1901, Teva Pharmaceutical Industries Ltd. is a global company specialising in the development, production and marketing of both generic and proprietary branded pharmaceuticals, as well as active pharmaceutical ingredients. For more than a century we have been growing and developing as an organisation, so that today we can proudly take our place among the world's top 20 pharmaceutical companies.

Teva is a multinational company engaged in the research, development, manufacturing and marketing of branded and generic pharmaceuticals. Each patient is our customer and deserves medicines of the highest quality. Quality of the highest standard is our business.

In January 2006 Teva acquired its Runcorn site, which now manufactures sterile products for use in the treatment of respiratory conditions such as asthma and chronic obstructive pulmonary disease. Despite the current economic downturn, Teva Runcorn is enjoying a period of sustained growth and as a result we're looking to recruit talented, highly skilled people to a number of key positions within the business.